Nonablative minimally invasive thermal therapies in the treatment of symptomatic benign prostatic hyperplasia

Current Opinion in Urology

Volumn 18, Issue 1, 2008, Pages 21-27

  D'Ancona, Franck C H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Benign prostatic hyperplasia; Minimal invasive treatment; Nonablative thermal therapy; Prostate

Indexed keywords

ANESTHESIA; COMPARATIVE STUDY; HEALTH CARE COST; HUMAN; HYPERTHERMIC THERAPY; OUTPATIENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; REVIEW; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; TREATMENT DURATION; ULTRASOUND THERAPY;

HEAT; HUMANS; MALE; PROSTATIC HYPERPLASIA; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 37349069502     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3282f20157     Document Type: Review

References (51)

1. Muschter R, Schorsch I, Danielli L, et al. Transurethral water-induced thermotherapy for the treatment of benign prostatic hyperplasia: a prospective multicenter clinical trial. J Urol 2000; 164:1565-1569.
2. Muschter R. Conductive heat: hot water-induced thermotherapy for ablation of prostatic tissue. J Endourol 2003; 17:609-616.
3. Bihrle R, Foster RS, Sanghvi NT, et al. High intensity focused ultrasound for the treatment of benign prostatic hyperplasia: early United States clinical experience. J Urol 1994; 151:1271-1275.
4. Mulligan ED, Lynch TH, Mulvin D, et al. High-intensity focused ultrasound in the treatment of benign prostatic hyperplasia. Br J Urol 1997; 79:177-180.
5. Madersbacher S, Schatzl G, Djavan B, et al. Long-term outcome of transrectal high-intensity focused ultrasound therapy for benign prostatic hyperplasia. Eur Urol 2000; 37:687-694.
6. Ragavan N, Philip J, Balasubramanian SP, et al. A randomized, controlled trial comparing lidocaine periprostatic nerve block, diclofenac suppository and both for transrectal ultrasound guided biopsy of prostate. J Urol 2005; 174:510-513.
7. Roehrborn CG, Issa MM, Bruskewitz RC, et al. Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study. Urology 1998; 51:415-421.
8. Zlotta AR, Giannakopoulos X, Maehlum O, et al. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003; 44:89-93.
9. Cimentepe E, Unsal A, Saglam R. Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months. J Endourol 2003; 17:103-107.
10. Hill B, Belville W, Bruskewitz R, et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 2004; 171 (6 Pt 1):2336-2340.
11. Schulman CC, Zlotta AR. TUNA: a promising new therapy for BPH. Contemp Urol 1995; 7:59-64.
12. Blute ML, Tomera KM, Hellerstein DK, et al. Transurethral microwave thermotherapy for management of benign prostatic hyperplasia: results of the United States Prostatron Cooperative Study. J Urol 1993; 150 (5 Pt 2):1591-1596.
13. Dahlstrand C, Walden M, Geirsson G, Pettersson S. Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up. Br J Urol 1995; 76:614-618.
14. de Wildt MJ, D'Ancona FC, Hubregtse M, et al. Three-year followup of patients treated with lower energy microwave thermotherapy. J Urol 1996; 156:1959-1963.
15. Devonec M, Tomera K, Perrin P. Review: transurethral microwave thermotherapy in benign prostatic hyperplasia. J Endourol 1993; 7:255-259.
16. Bolmsjo M, Wagrell L, Hallin A, et al. The heat is on-but how? A comparison of TUMT devices. Br J Urol 1996; 78:564-572.
17. D'Ancona FC, Francisca EA, Hendriks JC, et al. High energy transurethral thermotherapy in the treatment of benign prostatic hyperplasia: criteria to predict treatment outcome. Prostate Cancer Prostatic Dis 1999; 2:98-105.
18. D'Ancona FC, Francisca EA, Hendriks JC, et al. How to select patients for high-energy transurethral microwave thermotherapy. Urology 1999; 53:111-117.
19. D'Ancona FC, Francisca EA, Hendriks JC, et al. The predictive value of baseline variables in the treatment of benign prostatic hyperplasia using high-energy transurethral microwave thermotherapy. Br J Urol 1998; 82:808-813.
20. 3 were included. This study showed that also in patients with urinary retention and very large prostates, TUMT is a very affective treatment, with lower morbidity than TURP and enucleation surgery.
21. Aso Y, Abbou CC, Abrams P, et al. Clinical research criteria. In: Cockett ATK, Aso Y, Chatelain C, et al. editors. The 3rd International consultation on benign prostatic hyperplasia (BPH). Paris: International Consultation on Benign Prostatic Hyperplasia; 1995. pp. 451-468.
22. D'Ancona FC, Francisca EA, Witjes WP, et al. High energy thermotherapy versus transurethral resection in the treatment of benign prostatic hyperplasia: results of a prospective randomized study with 1 year of followup. J Urol 1997; 158:120-125.
23. D'Ancona FC, Francisca EA, Witjes WP, et al. Transurethral resection of the prostate vs high-energy thermotherapy of the prostate in patients with benign prostatic hyperplasia: long-term results. Br J Urol 1998; 81:259-264.
24. Mattiasson A, Wagrell L, Schelin S, et al. Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Urology 2007; 69:91-96.
25. Hoffman RM, MacDonald R, Monga M, Wilt TJ. Transurethral microwave thermotherapy vs transurethral resection for treating benign prostatic hyperplasia: a systematic review. BJU Int 2004; 94:1031-1036.
26. Fowler FJ Jr, Barry MJ. Quality of life assessment for evaluating benign prostatic hyperplasia treatments. An example of using a condition-specific index. Eur Urol 1993; 24 (Suppl 1):24-27.
27. Francisca EA, D'Ancona FC, Meuleman EJ, et al. Sexual function following high energy microwave thermotherapy: results of a randomized controlled study comparing transurethral microwave thermotherapy to transurethral prostatic resection. J Urol 1999; 161:486-490.
28. Rosen RC. Assessment of sexual dysfunction in patients with benign prostatic hyperplasia. BJU Int 2006; 97 (Suppl 2):29-33.
29. D'Ancona FC, van der Bij AK, Francisca EA, et al. Results of high-energy transurethral microwave thermotherapy in patients categorized according to the American Society of Anesthesiologists operative risk classification. Urology 1999; 53:322-328.
30. Ferakis N, Skolarikos A, Staios D, et al. Treatment characteristics and inherent prostatic features do not predict patient outcome after high-energy transurethral thermotherapy: a prospective study of prostalund feedback treatment. J Endourol 2006; 20:1075-1081. Efforts were made to define patient characteristics to predict clinical outcome of high energy transurethral thermotherapy. Although it is a small patient cohort it seems clear that parameters like cell-kill calculation alone is not able to predict the outcome.
31. D'Ancona FC, Albers YH, Kiemeney LA, et al. Can histopathology predict treatment outcome following high-energy transurethral microwave thermotherapy of the prostate? Results of a biopsy study. Prostate 1999; 40:28-36.
32. Roehrborn CG, Krongrad A, Mcconnell JD. Temperature mapping in the canine prostate during transurethrally-applied local microwave hyperthermia. Prostate 1992; 20:97-104.
33. Huidobro C, Bolmsjo M, Larson T, et al. Evaluation of microwave thermotherapy with histopathology, magnetic resonance imaging and temperature mapping. J Urol 2004; 171 (2 Pt 1):672-678.
34. Schelin S, Richthoff J. Experiences of a new device for mediating intraprostatic injections of drugs via the urethra [abstract]. J Urol 2006; 175 (4 suppl): 492.
35. Schelin S, Claezon A, Sundin A, Wagrell L. Effects of intraprostatic and periprostatic injections of mepivacaine epinephrine on intraprostatic blood flow during transurethral microwave thermotherapy: correlation with [15O]H2O-PET. J Endourol 2004; 18:965-970.
36. Gravas S, Laguna P, Kiemeney ALM, De La Rosette JMCJ. Durability of 30-min high energy transurethral microwave therapy for treatment of benign prostatic hyperplasia: a study of 213 patients with and without urinary retention. Urology 2007; 69:854-858.
37. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)-incidence, management, and prevention. Eur Urol 2006; 50:969-979.
38. Floratos DL, Kiemeney LA, Rossi C, et al. Long-term followup of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study. J Urol 2001; 165:1533-1538.
39. Thalmann GN, Mattei A, Treuthardt C, et al. Transurethral microwave therapy in 200 patients with a minimum followup of 2 years: urodynamic and clinical results. J Urol 2002; 167:2496-2501.
40. Miller PD, Kastner C, Ramsey EW, Parsons K. Cooled thermotherapy for the treatment of benign prostatic hyperplasia: Durability of results obtained with the targis system. Urology 2003; 61:1160-1164.
41. Tan AH, Nott L, Hardie WR, et al. Long-term results of microwave thermotherapy for symptomatic benign prostatic hyperplasia. J Endourol 2005; 19:1191-1195.
42. Ahmed M, Bell T, Lawrence WT, et al. Transurethral microwave thermotherapy (Prostatron version 2.5) compared with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a randomized, controlled, parallel study. Br J Urol 1997; 79:181-185.
43. Norby B, Nielsen HV, Frimodt-Moller PC. Transurethral interstitial laser coagulation of the prostate and transurethral microwave thermotherapy vs transurethral resection or incision of the prostate: results of a randomized, controlled study in patients with symptomatic benign prostatic hyperplasia. BJU Int 2002; 90:853-862.
44. Kobelt G, Spangberg A, Mattiasson A. The cost of feedback microwave thermotherapy compared with transurethral resection of the prostate for treating benign prostatic hyperplasia. BJU Int 2004; 93:543-548.
45. de la Rosette JJ, Floratos DL, Severens JL, et al. Transurethral resection vs microwave thermotherapy of the prostate: a cost-consequences analysis. BJU Int 2003; 92:713-718.
46. Stovsky MD, Griffiths RI, Duff SB. A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia. J Urol 2006; 176 (4 Pt 1):1500-1506. The authors compared minimal invasive therapies with a new surgical treatment modality (photoselective vaporization) and conclude that the latter is the most costeffective treatment option, although not minimally invasive.
47. Yu XH, McBean AM, Caldwell DS. Unequal use of new technologies by race: The use of new prostate surgeries (transurethral needle ablation, transurethral microwave therapy and laser) among elderly Medicare beneficiaries. J Urol 2006; 175:1830-1835.
48. Platz EA, Smit E, Curhan GC, et al. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in US men. Urology 2002; 59:877-883.
49. Djavan B, Seitz C, Roehrborn CG, et al. Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months. Urology 2001; 57:66-70.
50. Fitzpatrick JM. A critical evaluation of technological innovations in the treatment of symptomatic benign prostatic hyperplasia. Br J Urol 1998; 81 (Suppl 1): 56-63.
51. Barmoshe S, Zlotta AR. How do I treat and follow my TUNA patients? World J Urol 2006; 24:397-404. This article gives a complete overview of the TUNA treatment, technical aspects, new developments and challenges in relation to other treatment modalities and economic issues.